drugset
drugset / Trial / NCT00423709

Allogeneic Blood Stem Cell Transplantation

NCT00423709 ↗

Completed 46 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved with this strategy. 3. To assess the antitumor activity of this approach in high-risk HD patients and the possible presence of a graft-vs-HD effect.

Timeline

Start
1998-01
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Background Fludarabine Small molecule — Intravenous
Background Melphalan Small molecule — Intravenous

Indications

Hodgkins lymphoma